All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Amgen Inc.'s plan to buy out nephrology-focused Ilypsa Inc. for $420 million - thereby gaining a Phase II phosphate binder for chronic kidney disease - put little immediate fear into backers of Genzyme Corp., thanks to progress with the latter's CKD therapy Renvela. (BioWorld Today)